{"id":2876,"date":"2020-06-03T15:25:45","date_gmt":"2020-06-03T15:25:45","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&p=2876"},"modified":"2020-07-08T09:11:53","modified_gmt":"2020-07-08T09:11:53","slug":"artificial-cell-constructs-for-cellular-manipulation","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/artificial-cell-constructs-for-cellular-manipulation\/","title":{"rendered":"Artificial Cell Constructs For Cellular Manipulation"},"content":{"rendered":"

Artificial Cell Constructs For Cellular Manipulation<\/h2>\n

Artificial Particle Comprising At Least One Soluble Treg Cell Factor And At Least One Surface Bound Treg Cell Factor<\/p>\n<\/div>

<\/div><\/div><\/div>

Inventors:<\/strong> Steven Little PhD<\/p>\n

Patent Number:<\/strong> 13\/383,122<\/p>\n

\n
\n
\n

Abstract<\/h3>\n
\n
\n
The present invention contemplates induction of immunological tolerance thereby providing permanent allogcaft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div>
<\/div>
<\/div>